Capricor Soars on Key FDA Regulatory Breakthrough

Shares of Capricor Therapeutics experienced a significant 10% surge yesterday, closing at $6.79. This substantial gain was driven by a pivotal clarification from the U.S. Food and Drug Administration (FDA) concerning the regulatory pathway for its stem cell therapy, Deramiocel.

A Constructive Shift from Regulators

The recent development marks a notable turnaround for the biotechnology firm. Following a Type-A meeting with the regulatory agency, Capricor confirmed that the FDA has agreed to accept the already-completed HOPE-3 clinical study. This study will serve as the “additional study” requested in the Complete Response Letter issued back in July 2025. This agreement is a critical step, allowing the company to integrate the HOPE-3 data directly into its existing Biologics License Application (BLA), thereby facilitating a faster resumption of the review process.

Market experts immediately responded to the positive regulatory news, with several firms reaffirming their confidence in the stock on Friday:
– Maxim Group (Jason McCarthy): Buy rating
– Oppenheimer: Buy rating
– JonesTrading: Buy rating
– B. Riley Financial: Buy rating

Should investors sell immediately? Or is it worth buying Capricor Therapeutics?

This broad analyst support underscores the growing conviction in Deramiocel’s approval prospects. The therapy is intended to treat Duchenne muscular dystrophy, a severe genetic disorder.

Path Forward and Key Milestones

The FDA has also indicated a degree of flexibility in its assessment of the forthcoming data. Topline results from the HOPE-3 study, which enrolled 105 participants, are anticipated around the middle of the fourth quarter of 2025. The crucial near-term catalyst will be the release of this data in the coming weeks. A successful conclusion to the regulatory process could potentially set the stage for Deramiocel’s market launch by 2027.

The cooperative stance from the FDA represents a constructive change in direction after the setback earlier this year, positioning Capricor for a potentially accelerated approval timeline.